<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765593</url>
  </required_header>
  <id_info>
    <org_study_id>3398</org_study_id>
    <nct_id>NCT03765593</nct_id>
  </id_info>
  <brief_title>Biomarkers in Primary Sjögren's Syndrome</brief_title>
  <acronym>pSS</acronym>
  <official_title>Gene Expression of Interferon (INF) and B Lymphocyte Biomarkers as Markers of Systemic Affectation and Lymphoproliferative Disease in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Council of Scientific and Technical Research, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Council of Scientific and Technical Research, Argentina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical spectrum of primary Sjogren Syndrome (pSS)ranges from sicca syndrome to systemic
      involvement (extraglandular manifestations), including a large number of manifestations that
      may be the form of presentation or appear after the disease is diagnosed, and that clearly
      mark the prognosis of the disease.

      Gene expression levels of Interferon (INF) and B Lymphocyte Biomarkers as Markers of Systemic
      Affectation and Lymphoproliferative Disease in, together with clinical and laboratory
      parameters, will provide significant information about the risk of developing hematological
      neoplasms in patients with pSS at different stages of the disease, and lead to better
      management of the disease treatment and therapeutic behaviors.

      Using the proposed technique allows us to study the gene expression at the mRNA level of each
      biomarker, which allows us to anticipate the irreversible changes that take place due to the
      progress of the pathology in progress, since the molecular changes precede the histological
      changes and in the pathological diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project, address the value of these proposed biomarkers in pSS with regard to disease
      activity and risk stratification of pSS subsets. The investigator's group aim to determine if
      the proposed biomarkers and their gene expression in saliva, peripheral blood and minor
      salivary gland samples in patients with pSS are increased to know the degree of their
      usefulness in daily clinical practice, to indicate which patients have a highest risk of
      developing a hematological malignancy and to know if these biomarkers are useful to recognize
      patients who have greater activity of the disease to be able to use it in the follow-up of
      the disease and as a future responder of the new biological therapies against B cells, INF
      and monocytes.

      Gene expression is a highly regulated mechanism that controls the function and adaptability
      of all living cells. The field of gene expression analysis has undergone important advances
      in biomedical research. Today, quantification techniques of mRNA expression have led to
      improvements in the identification of the gene and the sub-classification of the disease, for
      example, the expression of specific genes (mRNA) can be quantified by reverse transcription
      and PCR in quantitative real time. This is the most sensitive technique available to detect
      and quantify mRNA, where extremely small sample sizes can be used in mRNA quantification.
      Molecular changes precede histological changes and clinicians in the diagnosis of a
      pathology. For this reason, studying gene expression at the mRNA level allows us to
      anticipate irreversible changes that take place due to the progress of the pathology in
      progress.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in salivary gland biopsy samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in blood samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in saliva samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulins</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in IgG, IgM and IgA levels at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement levels C3 and C4</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in complement levels at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Factor</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in titer of rheumatoid factors at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryoglobulins</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in titer of cryoglobulins at 24 months.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Sjögren Syndrome</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Study group 1</arm_group_label>
    <description>Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 2</arm_group_label>
    <description>Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 3</arm_group_label>
    <description>Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy Salivary Gland</intervention_name>
    <description>A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group 1</arm_group_label>
    <arm_group_label>Study group 2</arm_group_label>
    <arm_group_label>Study group 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Salivary gland, saliva, blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with sicca and primary Sjogren Syndrome will be recruited from multiple sites.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients: cross sectionally patients will be included for clinical suspicion of
             primary SS or with the diagnosis already established in Rheumatology unit.

        The following inclusion criteria will be applied to the study:

          -  Age &gt; 18 years

          -  Informed consent of the patient.

        Exclusion Criteria:

          -  Impossibility of obtaining consent (cognitive impairment, other causes).

          -  Associated systemic autoimmune or rheumatological diseases.

          -  Chronic viral infections (HCV, HBV, HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Soledad Retamozo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INICSA-Universidad Nacional de Córdoba-CONICET, Córdoba, Argentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Soledad Retamozo, MD, PhD</last_name>
    <phone>005493516981622</phone>
    <email>soleretamozo@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Cuestas, MD, PhD</last_name>
    <phone>005493516609303</phone>
    <email>eduardo.cuestas@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Retamozo S, Flores-Chavez A, Consuegra-Fernández M, Lozano F, Ramos-Casals M, Brito-Zerón P. Cytokines as therapeutic targets in primary Sjögren syndrome. Pharmacol Ther. 2018 Apr;184:81-97. doi: 10.1016/j.pharmthera.2017.10.019. Epub 2017 Oct 29. Review.</citation>
    <PMID>29092775</PMID>
  </reference>
  <reference>
    <citation>Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;89(6):888-92.</citation>
    <PMID>102228</PMID>
  </reference>
  <reference>
    <citation>Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjögren's syndrome. Curr Rheumatol Rep. 2003 Aug;5(4):311-6. Review.</citation>
    <PMID>14531959</PMID>
  </reference>
  <reference>
    <citation>Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002 Mar;46(3):741-7.</citation>
    <PMID>11920410</PMID>
  </reference>
  <reference>
    <citation>Brito-Zerón P, Retamozo S, Gheitasi H, Ramos-Casals M. Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. Drugs. 2016 Dec;76(18):1799.</citation>
    <PMID>27905085</PMID>
  </reference>
  <reference>
    <citation>Rose T, Grützkau A, Hirseland H, Huscher D, Dähnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013 Oct;72(10):1639-45. doi: 10.1136/annrheumdis-2012-201586. Epub 2012 Oct 31.</citation>
    <PMID>23117242</PMID>
  </reference>
  <results_reference>
    <citation>Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 2000 Apr;43(4):908-16.</citation>
    <PMID>10765938</PMID>
  </results_reference>
  <results_reference>
    <citation>Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015 Nov;14(11):1019-22. doi: 10.1016/j.autrev.2015.07.002. Epub 2015 Jul 8. Review.</citation>
    <PMID>26162302</PMID>
  </results_reference>
  <results_reference>
    <citation>Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, De Vita S. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;52(2):276-81. doi: 10.1093/rheumatology/kes180. Epub 2012 Aug 9.</citation>
    <PMID>22879463</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3.</citation>
    <PMID>10398604</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747-56.</citation>
    <PMID>10359578</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003 Feb;62(2):168-71.</citation>
    <PMID>12525388</PMID>
  </results_reference>
  <results_reference>
    <citation>Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis. 2011 Aug;70(8):1363-8. doi: 10.1136/ard.2010.144782.</citation>
    <PMID>21715359</PMID>
  </results_reference>
  <results_reference>
    <citation>Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol. 2004 Apr;202(4):496-502.</citation>
    <PMID>15095277</PMID>
  </results_reference>
  <results_reference>
    <citation>Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol. 2005 Nov;117(2):168-76. Epub 2005 Aug 26.</citation>
    <PMID>16126006</PMID>
  </results_reference>
  <results_reference>
    <citation>Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 2007 Apr;56(4):1134-44.</citation>
    <PMID>17393395</PMID>
  </results_reference>
  <results_reference>
    <citation>Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005 May;52(5):1534-44.</citation>
    <PMID>15880807</PMID>
  </results_reference>
  <results_reference>
    <citation>Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008 Jul;38(7):2024-33. doi: 10.1002/eji.200738008.</citation>
    <PMID>18581327</PMID>
  </results_reference>
  <results_reference>
    <citation>Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, Wildenberg ME, Beumer W, Drexhage HA, Versnel MA. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013 May;72(5):728-35. doi: 10.1136/annrheumdis-2012-201381. Epub 2012 Jun 26.</citation>
    <PMID>22736090</PMID>
  </results_reference>
  <results_reference>
    <citation>Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14.</citation>
    <PMID>26183766</PMID>
  </results_reference>
  <results_reference>
    <citation>Rose T, Szelinski F, Lisney A, Reiter K, Fleischer SJ, Burmester GR, Radbruch A, Hiepe F, Grützkau A, Biesen R, Dörner T. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. RMD Open. 2016 Dec 30;2(2):e000292. doi: 10.1136/rmdopen-2016-000292. eCollection 2016.</citation>
    <PMID>28123773</PMID>
  </results_reference>
  <results_reference>
    <citation>Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum. 2005 Jun;52(6):1773-84.</citation>
    <PMID>15934082</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Council of Scientific and Technical Research, Argentina</investigator_affiliation>
    <investigator_full_name>Maria Soledad Retamozo</investigator_full_name>
    <investigator_title>Research Assistant</investigator_title>
  </responsible_party>
  <keyword>Primary Sjogren Syndrome</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

